Parainfluenza virus type 3

Parainfluenza virus type 3 (HPIV-3) is a respiratory virus belonging to the Paramyxoviridae family. It is a major cause of acute respiratory illness in children and can cause illness in people of all ages. The virus can cause a wide range of clinical manifestations, including mild respiratory infections, bronchiolitis, and pneumonia. Young children, especially those with pre-existing lung problems, may develop serious complications. Parainfluenza 3 can also cause outbreaks in closed settings, such as daycare centers and schools.

History of the disease and interesting historical facts

The parainfluenza virus was first isolated in 1956 and has since attracted the attention of researchers and medical professionals worldwide. Parainfluenza 3 was described as a virus that causes acute respiratory infections in children. Interesting historical facts include that the first major outbreak was reported in Hong Kong in 1979, which led to active research into the development of vaccines. Despite advances in medicine, there is still no specific vaccine to prevent the infection, which poses a challenge for the medical community to develop effective preventive measures.

Epidemiology (statistics of disease occurrence)

Epidemiological studies show that the incidence of parainfluenza virus type 3 is significant, especially among children. According to the World Health Organization, the virus causes approximately 20-30% cases of hospitalization among young children with acute respiratory infections each year. The incidence increases significantly in the autumn-winter period, with peak levels in the cold season. In adults, the disease often occurs in a mild form, but can lead to an exacerbation of chronic diseases.

Genetic predisposition to this disease

At present, no specific genes have been identified that directly predispose to infections caused by parainfluenza virus type 3. However, a general genetic predisposition to viral infections may be associated with mutations in genes responsible for the immune response. For example, polymorphisms in genes encoding cytokines and receptors may affect susceptibility to respiratory viral infections. Research shows that a weakened immune system, as a consequence of a genetic factor, may lead to a more severe course of the disease.

Risk factors for the development of this disease

There are several risk factors that contribute to the development of infection caused by parainfluenza virus type 3. These include:

• Problems with the immune system: the presence of diseases that weaken the immune response.
• Age: Young children and older adults are at greater risk.
• Respiratory diseases such as asthma and chronic bronchitis.
• Short-term or long-term stay in closed spaces, especially during disease outbreaks.
• Contact with infected people and low socioeconomic status, which may limit access to health care.

Diagnosis of this disease

Diagnosis of parainfluenza virus type 3 infection is based on clinical symptoms and laboratory tests. The main symptoms include:

• High temperature
• Cough accompanied by sputum production
• Difficulty breathing and wheezing
• Sore throat and rhinitis

Laboratory tests may include:

• Polymerase chain reaction (PCR) to detect the presence of viral RNA.
• Immunofluorescence methods for detection of viral antigens.

Radiological tests such as chest X-rays may be used to rule out other conditions such as pneumonia. The differential diagnosis should include other respiratory viral infections such as influenza and rhinovirus infection.

Treatment

Treatment for parainfluenza 3 viral infection is mostly symptomatic, including:

• Rest and drink plenty of fluids.
• Analgesics and antipyretics to reduce temperature and pain.

Pharmacological treatment may include:

• Bronchodilators to ease breathing.
• Probiotics and immunostimulants that can help restore microflora.

Surgery may be required in cases where complications arise, such as a lung abscess, but such cases are rare.

List of medications used to treat this disease

Among the drugs prescribed for the treatment of this disease, the following can be distinguished:

• Paracetamol
• Ibuprofen
• Acetylcysteine
• Salbutamol
• Immunostimulants such as interferon

Disease monitoring

Monitoring of the patient's condition includes regular follow-up examinations until complete recovery, and it is also possible to use

hospitalization in severe cases. The prognosis is usually good, but complications such as bronchitis or pneumonia may develop, especially in predisposed patients such as young children or those with underlying medical conditions.

Age-related features of the disease

In young children, parainfluenza virus type 3 may present with more pronounced clinical symptoms, often with complications in the form of bronchiolitis. In older people, the disease may be mild, but their susceptibility to complications and relapses is significantly higher.

Questions and Answers

• How is parainfluenza virus type 3 transmitted?
  The virus is transmitted by airborne droplets, especially in closed spaces where there are large crowds of people.
• What is the duration of treatment for parainfluenza 3?
  In most cases, symptoms resolve within 7-10 days, treatment is mainly symptomatic.
• Can parainfluenza 3 infection be prevented?
  There is no specific vaccine, but good hygiene and strengthening the immune system can reduce the risk.
• What are the main complications of parainfluenza virus 3 infection?
  Complications may include pneumonia and bronchiolitis, especially in young children and people with chronic medical conditions.
• Can adults get parainfluenza 3?
  Yes, adults can get sick, but in most cases the infection is mild.